This filing provides updated analyst expectations and ratings for Abbott Laboratories (ABT) ahead of its Q3 earnings report. The consensus estimates suggest an increase in both EPS and revenue year-over-year, with several analysts maintaining or upgrading ratings and raising price targets, indicating a generally positive sentiment.
The filing highlights that Abbott Laboratories (ABT) is set to release its Q3 earnings, with analysts forecasting growth in both EPS and revenue compared to the prior year. Several prominent analysts have recently reiterated 'Buy' or 'Overweight' ratings, with some increasing their price targets, suggesting a bullish outlook for the company. This positive analyst sentiment, coupled with recent FDA approval for CardioMEMS HF System updates, could create short-term upward momentum for ABT shares leading into the earnings call. For traders, the key opportunity lies in potential upside if ABT meets or exceeds these elevated expectations, while the risk is a potential pullback if the actual results disappoint despite the positive analyst revisions.